Clinical and Molecular Hepatology (Clin Mol Hepatol, CMH)

Review

Liquid biopsy in hepatocellular carcinoma: Challenges, advances, and clinical implications

Jaeho Park, Yi-Te Lee, Vatche G. Agopian, Jessica S Liu, Ekaterina K. Koltsova, Sungyong You, Yazhen Zhu, Hsian-Rong Tseng, Ju Dong Yang

Clin Mol Hepatol. 2025;31(Suppl):S255-S284. Published online November 28, 2024

DOI: https://doi.org/10.3350/cmh.2024.0541

View: 1890 Download: 190 Web of Science: 1

Original Article

Exploring methylation signatures for high de novo recurrence risk in hepatocellular carcinoma

Da-Won Kim, Jin Hyun Park, Suk Kyun Hong, Min-Hyeok Jung, Ji-One Pyeon, Jin-Young Lee, Kyung-Suk Suh, Nam-Joon Yi, YoungRok Choi, Kwang-Woong Lee, Young-Joon Kim

Clin Mol Hepatol. 2025;31(2):563-576. Published online January 13, 2025

DOI: https://doi.org/10.3350/cmh.2024.0899

View: 1151 Download: 83

Longitudinal profile of plasma pregenomic RNA in patients with chronic hepatitis B infection on long-term nucleoside analogues and its interaction with clinical parameters

Lung-Yi Mak, Mark Anderson, Michael Stec, Matthew Shing-Hin Chung, Danny Ka-Ho Wong, Rex Wan-Hin Hui, Wai-Kay Seto, Gavin Cloherty, Man-Fung Yuen

Clin Mol Hepatol. 2025;31(2):460-473. Published online December 26, 2024

DOI: https://doi.org/10.3350/cmh.2024.0724

View: 1176 Download: 103

Reply to Correspondence

Reply to correspondence on “Genomic biomarkers to predict response to atezolizumab plus bevacizumab immunotherapy in hepatocellular carcinoma: Insights from the IMbrave150 trial”

Hiroaki Kanzaki, Yujin Hoshida

Clin Mol Hepatol. 2025;31(1):e121-e122. Published online October 11, 2024

DOI: https://doi.org/10.3350/cmh.2024.0886

View: 989 Download: 37

Correspondence

Correspondence to letter to the editor on “Genomic biomarkers to predict response to atezolizumab plus bevacizumab immunotherapy in hepatocellular carcinoma: Insights from the IMbrave150 trial”

Sung Hwan Lee, Sun Young Yim, Ji Hoon Kim, Sunyoung S Lee, Ahmed O Kaseb, Peng Wei, Ju-Seog Lee

Clin Mol Hepatol. 2025;31(1):e110-e112. Published online October 2, 2024

DOI: https://doi.org/10.3350/cmh.2024.0828

View: 1057 Download: 49

Correspondence to editorial 2 on “Genomic biomarkers to predict response to atezolizumab plus bevacizumab immunotherapy in hepatocellular carcinoma: insights from the IMbrave150 trial”

Sun Young Yim, Sung Hwan Lee, Ji Hoon Kim, Sunyoung S Lee, Ahmed O Kaseb, Ju-Seog Lee

Clin Mol Hepatol. 2025;31(1):e84-e86. Published online October 7, 2024

DOI: https://doi.org/10.3350/cmh.2024.0830

View: 934 Download: 33

Correspondence to editorial 1 on “Genomic biomarkers to predict response to atezolizumab plus bevacizumab immunotherapy in hepatocellular carcinoma: insights from the IMbrave150 Trial”

Sung Hwan Lee, Sun Young Yim, Ji Hoon Kim, Sunyoung S. Lee, Ahmed O. Kaseb, Ju-Seog Lee

Clin Mol Hepatol. 2025;31(1):e81-e83. Published online October 7, 2024

DOI: https://doi.org/10.3350/cmh.2024.0829

View: 1041 Download: 35 Crossref: 1

Letter to the Editor

Comprehensive analysis of transcriptomic biomarkers for predicting response to atezolizumab plus bevacizumab immunotherapy in hepatocellular carcinoma

Binghua Li, Jingyuan Wen, Zhu Xu, Peng Yan, Bing Han, Decai Yu

Clin Mol Hepatol. 2025;31(1):e31-e34. Published online September 20, 2024

DOI: https://doi.org/10.3350/cmh.2024.0628

View: 1239 Download: 109 Crossref: 2

Editorial

Personalized approaches to the treatment of hepatocellular carcinoma using immune checkpoint inhibitors: Editorial on “Genomic biomarkers to predict response to atezolizumab plus bevacizumab immunotherapy in hepatocellular carcinoma: Insights from the IMbrave150 trial”

Naoshi Nishida

Clin Mol Hepatol. 2025;31(1):311-315. Published online September 3, 2024

DOI: https://doi.org/10.3350/cmh.2024.0739

View: 1169 Download: 69 Web of Science: 2 Crossref: 4

Transcriptomic signature in advanced hepatocellular carcinoma tissue to predict combination immunotherapy response: Editorial on “Genomic biomarkers to predict response to atezolizumab plus bevacizumab immunotherapy in hepatocellular carcinoma: Insights from the IMbrave150 trial”

Hiroaki Kanzaki, Yujin Hoshida

Clin Mol Hepatol. 2025;31(1):308-310. Published online August 30, 2024

DOI: https://doi.org/10.3350/cmh.2024.0726

View: 1121 Download: 76 Web of Science: 1 Crossref: 1

Unveiling the distinctive gut microbiota and metabolites in liver cirrhosis and its complications: Novel diagnostic biomarkers: Editorial on “Gut microbiome and metabolome signatures in liver cirrhosis-related complications”

Soon Kyu Lee, Jong Young Choi

Clin Mol Hepatol. 2025;31(1):301-303. Published online August 30, 2024

DOI: https://doi.org/10.3350/cmh.2024.0716

View: 1122 Download: 75 Crossref: 1

Correspondence

Correspondence to editorial on “Multiomics profiling of buffy coat and plasma unveils etiology-specific signatures in hepatocellular carcinoma”

Su Bin Lim, Hyo Jung Cho

Clin Mol Hepatol. 2024;30(4):1009-1011. Published online May 20, 2024

DOI: https://doi.org/10.3350/cmh.2024.0368

View: 1682 Download: 75 Crossref: 1

Original Article

Gut microbiome and metabolome signatures in liver cirrhosis-related complications

Satya Priya Sharma, Haripriya Gupta, Goo-Hyun Kwon, Sang Yoon Lee, Seol Hee Song, Jeoung Su Kim, Jeong Ha Park, Min Ju Kim, Dong-Hoon Yang, Hyunjoon Park, Sung-Min Won, Jin-Ju Jeong, Ki-Kwang Oh, Jung A Eom, Kyeong Jin Lee, Sang Jun Yoon, Young Lim Ham, Gwang Ho Baik, Dong Joon Kim, Ki Tae Suk

Clin Mol Hepatol. 2024;30(4):845-862. Published online July 25, 2024

DOI: https://doi.org/10.3350/cmh.2024.0349

View: 5474 Download: 992 Web of Science: 6 Crossref: 6

Editorial

Unveiling etiology-specific blood biomarkers in hepatocellular carcinoma: A gateway to personalized medicine: Editorial on “Multiomics profiling of buffy coat and plasma unveils etiology-specific signatures in hepatocellular carcinoma”

Joseph C. Ahn, Ju Dong Yang

Clin Mol Hepatol. 2024;30(4):689-691. Published online May 14, 2024

DOI: https://doi.org/10.3350/cmh.2024.0348

View: 1773 Download: 41 Crossref: 1

Correspondence

Correspondence on Editorial regarding “Identification of signature gene set as highly accurate determination of MASLD progression”

Sungju Jung, Sumin Yoon, Jong Hoon Park, Yeon-Su Lee, Kyung Hyun Yoo

Clin Mol Hepatol. 2024;30(2):287-290. Published online February 23, 2024

DOI: https://doi.org/10.3350/cmh.2024.0136

View: 2912 Download: 78 Crossref: 1

Original Article

Identification of signature gene set as highly accurate determination of metabolic dysfunction-associated steatotic liver disease progression

Sumin Oh, Yang-Hyun Baek, Sungju Jung, Sumin Yoon, Byeonggeun Kang, Su-hyang Han, Gaeul Park, Je Yeong Ko, Sang-Young Han, Jin-Sook Jeong, Jin-Han Cho, Young-Hoon Roh, Sung-Wook Lee, Gi-Bok Choi, Yong Sun Lee, Won Kim, Rho Hyun Seong, Jong Hoon Park, Yeon-Su Lee, Kyung Hyun Yoo

Clin Mol Hepatol. 2024;30(2):247-262. Published online January 26, 2024

DOI: https://doi.org/10.3350/cmh.2023.0449

View: 5315 Download: 301 Web of Science: 10 Crossref: 9

Prognostic value of ultra-low-pass whole-genome sequencing of circulating tumor DNA in hepatocellular carcinoma under systemic treatment

Miguel Sogbe, Idoia Bilbao, Francesco P. Marchese, Jon Zazpe, Annarosaria De Vito, Marta Pozuelo, Delia D’Avola, Mercedes Iñarrairaegui, Carmen Berasain, Maria Arechederra, Josepmaria Argemi, Bruno Sangro

Clin Mol Hepatol. 2024;30(2):177-190. Published online December 29, 2023

DOI: https://doi.org/10.3350/cmh.2023.0426

View: 9374 Download: 336 Web of Science: 10 Crossref: 12

Review

Noninvasive serum biomarkers for liver fibrosis in NAFLD: current and future

Tina Reinson, Ryan M. Buchanan, Christopher D. Byrne

Clin Mol Hepatol. 2023;29(Suppl):S157-S170. Published online November 22, 2022

DOI: https://doi.org/10.3350/cmh.2022.0348

View: 6286 Download: 350 Web of Science: 28 Crossref: 28

Noninvasive serum biomarkers for liver steatosis in nonalcoholic fatty liver disease: Current and future developments

Sang Bong Ahn

Clin Mol Hepatol. 2023;29(Suppl):S150-S156. Published online January 25, 2023

DOI: https://doi.org/10.3350/cmh.2022.0362

View: 6035 Download: 265 Web of Science: 13 Crossref: 15

Noninvasive imaging biomarkers for liver fibrosis in nonalcoholic fatty liver disease: current and future

Jung Hwan Yu, Han Ah Lee, Seung Up Kim

Clin Mol Hepatol. 2023;29(Suppl):S136-S149. Published online December 12, 2022

DOI: https://doi.org/10.3350/cmh.2022.0436

View: 6239 Download: 265 Web of Science: 28 Crossref: 29

Non-invasive imaging biomarkers for liver steatosis in non-alcoholic fatty liver disease: present and future

Asako Nogami, Masato Yoneda, Michihiro Iwaki, Takashi Kobayashi, Yasushi Honda, Yuji Ogawa, Kento Imajo, Satoru Saito, Atsushi Nakajima

Clin Mol Hepatol. 2023;29(Suppl):S123-S135. Published online December 12, 2022

DOI: https://doi.org/10.3350/cmh.2022.0357

View: 5789 Download: 234 Web of Science: 14 Crossref: 15

Hepatorenal syndrome: Current concepts and future perspectives

Chan-Young Jung, Jai Won Chang

Clin Mol Hepatol. 2023;29(4):891-908. Published online April 13, 2023

DOI: https://doi.org/10.3350/cmh.2023.0024

View: 10082 Download: 1,362 Web of Science: 9 Crossref: 10

Neuropilins as potential biomarkers in hepatocellular carcinoma: a systematic review of basic and clinical implications

Paula Fernández-Palanca, Tania Payo-Serafín, Carolina Méndez-Blanco, Beatriz San-Miguel, María J. Tuñón, Javier González-Gallego, José L. Mauriz

Clin Mol Hepatol. 2023;29(2):293-319. Published online February 1, 2023

DOI: https://doi.org/10.3350/cmh.2022.0425

View: 5983 Download: 130 Web of Science: 11 Crossref: 11

Utility of combining PIVKA-II and AFP in the surveillance and monitoring of hepatocellular carcinoma in the Asia-Pacific region

Do Young Kim, Bao Nguyen Toan, Chee-Kiat Tan, Irsan Hasan, Lyana Setiawan, Ming-Lung Yu, Namiki Izumi, Nguyen Nguyen Huyen, Pierce Kah-Hoe Chow, Rosmawati Mohamed, Stephen Lam Chan, Tawesak Tanwandee, Teng-Yu Lee, Thi Thanh Nguyen Hai, Tian Yang, Woo-Chang Lee, Henry Lik Yuen Chan

Clin Mol Hepatol. 2023;29(2):277-292. Published online January 30, 2023

DOI: https://doi.org/10.3350/cmh.2022.0212

View: 10833 Download: 635 Web of Science: 68 Crossref: 71

Correspondence

Correspondence on Editorial regarding “HBV pgRNA and HBcrAg reductions at week 4 predict favourable HBsAg response upon long-term nucleos(t)ide analogue in CHB”

Lung-Yi Mak, Wai-Kay Seto, Man-Fung Yuen

Clin Mol Hepatol. 2023;29(1):191-193. Published online November 22, 2022

DOI: https://doi.org/10.3350/cmh.2022.0410

View: 3664 Download: 75

Editorial

New biomarkers of hepatitis B virus (HBV) infection: HBV RNA and HBV core-related antigen, new kids on the block?

Young-Suk Lim

Clin Mol Hepatol. 2023;29(1):118-119. Published online November 29, 2022

DOI: https://doi.org/10.3350/cmh.2022.0413

View: 4360 Download: 193 Web of Science: 6 Crossref: 4

Original Article

Decreased vitamin D-binding protein level portends poor outcome in acute-on-chronic liver failure caused by hepatitis B virus

Daxian Wu, Qunfang Rao, Zhongyang Xie, Xiaoqing Zhu, Yuanmei Che, Jian Wu, Hainv Gao, Jingyu Zhang, Zhouhua Hou, Xiaoyu Cheng, Zeyu Sun

Clin Mol Hepatol. 2022;28(4):912-925. Published online July 28, 2022

DOI: https://doi.org/10.3350/cmh.2022.0121

View: 5652 Download: 157 Web of Science: 1 Crossref: 1

Discovery of dipeptidyl peptidase-4 inhibitor specific biomarker in non-alcoholic fatty liver disease mouse models using modified basket trial

Ju Hee Oh, Dae Won Jun, Hye Young Kim, Seung Min Lee, Eileen L. Yoon, Jungwook Hwang, Jung Hwan Park, Hanbi Lee, Wankyu Kim, Hyunsung Kim

Clin Mol Hepatol. 2022;28(3):497-509. Published online April 28, 2022

DOI: https://doi.org/10.3350/cmh.2022.0019

View: 7387 Download: 180 Web of Science: 9 Crossref: 8

Editorial

A crystal ball to forecast treatment responsiveness in nonalcoholic fatty liver disease

Seonghwan Hwang, Won Kim

Clin Mol Hepatol. 2022;28(3):478-480. Published online June 16, 2022

DOI: https://doi.org/10.3350/cmh.2022.0143

View: 4116 Download: 96

Review

Three heads are better than two: Hepatitis B core-related antigen as a new predictor of hepatitis B virus-related hepatocellular carcinoma

Jer-Wei Wu, Jia-Horng Kao, Tai-Chung Tseng

Clin Mol Hepatol. 2021;27(4):524-534. Published online February 23, 2021

DOI: https://doi.org/10.3350/cmh.2021.0012

View: 14744 Download: 380 Web of Science: 24 Crossref: 27

1 | 2 |

Viewed By 10475	Epidemiology of metabolic dysfunction-associated steatotic liver disease
Viewed By 7409	MAFLD: How is it different from NAFLD?
Viewed By 5352	Global incidence and prevalence of nonalcoholic fatty liver disease
Viewed By 4780	Assessing the performance of ChatGPT in answering questions regarding cirrhosis and hepatocellular carcinoma
Viewed By 4763	Hepatocellular carcinoma: updates on epidemiology, surveillance, diagnosis and treatment

Cited By 338	Assessing the performance of ChatGPT in answering questions regarding cirrhosis and hepatocellular carcinoma
Cited By 305	Global incidence and prevalence of nonalcoholic fatty liver disease
Cited By 210	MAFLD: How is it different from NAFLD?
Cited By 104	Pathogenesis and treatment of non-alcoholic steatohepatitis and its fibrosis
Cited By 104	Non-alcoholic fatty liver disease: Definition and subtypes

Search